信達生物(1801.HK)成功公開配售融資23.5133億港元
格隆匯10月4日丨信達生物(1801.HK)今天宣佈以每股24.60港元配售9700萬股新股,成功融資23.5133億港元。配售價格相當於10月3日收市價26.4港元折讓約6.82%,及在配售及認購協議日期前五個連續交易日在聯交所公佈的平均收市價每股約25.26港元上折讓約2.61%。配售及認購股份數額相當於信達生物現有已發行股本約8.37%,佔比公司擴大後股本7.73%。本次公司將發行全新股的方式融資,並稱全部的融資款項將被用於推進產品線上除原IPO招股書上所披露的核心產品外其他關鍵產品的研發,例如三種從Incyte公司引進的處於晚期臨牀和註冊試驗階段的產品,目前正處於I期臨牀階段的兩種同類世界首創雙特異性生物藥產品IBI-302(抗VEGF/抗補體雙特異性融合蛋白)和 IBI-318(抗PD-1/抗PD-L1雙特異性抗體,與禮來公司共同合作開發)等,同時也將用於公司擴大未來產能和其他一般用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.